Cargando…
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to current therapies and invariably recurs. Despite some advancements in anti-glioma therapies, patients’ prognosis remains poor. Toll-like receptors (TLRs) act as the first line of defense in the immune system...
Autores principales: | Xun, Yang, Yang, Hua, Kaminska, Bozena, You, Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555307/ https://www.ncbi.nlm.nih.gov/pubmed/34715891 http://dx.doi.org/10.1186/s13045-021-01191-2 |
Ejemplares similares
-
Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014) -
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022) -
Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014) -
Toll-like Receptors and Thrombopoiesis
por: Tang, Xiaoqin, et al.
Publicado: (2023) -
Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
por: Pahlavanneshan, Saghar, et al.
Publicado: (2021)